KDM1A and cancer: We used the two specific LSD1 inhibitors, 2-PCPA and GSK-LSD1, in combination with two common anti-cancer drugs, doxorubicin and paclitaxel, and applied different schemes regarding dosage, treatment time, and serial drug administration (data not shown).